Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Martek Biosciences---- future biotech cash cow! -- Ignore unavailable to you. Want to Upgrade?

To: david nordic who wrote (227)	4/29/2005 10:54:55 AM
From: Robert Douglas	Read Replies (1) \| Respond to of 258

It's hard for a business to create a product when there is only one supplier of an essential component. Formula companies have had to introduce products carefully as the supply of DHA and ARA from Martek has been doled out stingily. That these companies did some double ordering is not surprising and now that supplies are finally available in large quantities these stocks become unnecessary. The silver lining is now we can expect formula producers to proceed aggressively in completing the 100% adoption of DHA into infant formula. Furthermore the science behind this seems to be pushing for larger proportions which will increase the ultimate size of the end market.